ARVO Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kapur, R.
Right arrow Articles by Lim, J. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kapur, R.
Right arrow Articles by Lim, J. I.
Invest Ophthalmol Vis Sci 2010;51: E-Abstract 3324.
© 2010 ARVO


3324—D805

The Safe and Non-Toxic Dose of Intravitreal Micafungin and Caspofungin in a Rabbit Model

R. Kapur1, B. Kim2A, E. Y. Tu2A, A. Birnbaum2A, R. Fiscella2B, S. Navare2A, M. P. Blair2A, D. P. Edward3, J. Carroll4 and J. I. Lim2A

1Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin
AOphthalmology, BPharmacy/Ophthalmology, 2Univ of Illinois, Chicago, Illinois
3Ophthalmology, Summa Health System, Akron, Ohio
4Eye Institute, Med Coll of Wisconsin, Milwaukee, Wisconsin

Commercial Relationships: R. Kapur, None; B. Kim, None; E.Y. Tu, None; A. Birnbaum, None; R. Fiscella, None; S. Navare, None; M.P. Blair, None; D.P. Edward, None; J. Carroll, None; J.I. Lim, None.

Support: Illinois Society for Prevention of Blindness Scientific Research Award, Cless Retina Research Fund, NEI Core Grant for Vision Research (P30 EY001792)

Abstract

Purpose:Determine safe intravitreal (IV) dosing of the antifungal echinocandins, caspofungin (C) and micafungin (M), utilizing a multitest regimen in a New Zealand albino rabbit model.

Methods:Experiments were carried out in accordance with ARVO principles of animal care/Animal Care Committee at University of Illinois, Chicago. 17 rabbits (34 eyes) were randomized to IV injections of normal saline (NS) (n=5), micafungin (2 mg/0.1ml (n=2), 0.5 mg/0.1 ml (n=2), 0.2 mg/0.1 ml (n=3), 0.05 mg/0.1 ml (n=5), 0.025 mg/0.1 ml (n=4)) & caspofungin (0.5 mg/0.1 ml (n=2), 0.2 mg/0.1 ml (n=2), 0.05 mg/0.1ml (n=5), 0.025 mg/0.1 ml (n=4)). Rabbits were sacrificed at post-operative day (POD) 1 or 7. Anterior/posterior segment inflammation grading, spectral domain optical coherence tomography (OCT) and full field electroretinograms (ERG) were performed on POD 0 & day of sacrifice. ERGs with scotopic, maximal combined, & photopic responses were recorded. A decrease of 30% in a/b wave amplitudes was considered significant. Histopathology was performed to assess for inflammation/structural damage.

Results:Only eyes administered ≥ 0.2 mg/0.1ml concentrations of micafungin or caspofungin displayed signs of anterior segment inflammation &/or retinal whitening. Lower concentrations (M&C) and the NS group showed no clinically detectable changes. A dose response was noted for significant changes in a & b wave amplitude in both M & C groups. The 0.025 mg/0.1 ml dose of M & the NS group demonstrated no significant changes on ERG. OCT demonstrated no change in retinal thickness regardless of dose, drug, or duration. Loss of the outer photoreceptor complex was noted in a dose response fashion for both M & C. The 0.025 mg/0.1 ml dose of M & the NS group demonstrated no architectural changes on OCT. Histopathology also demonstrated increasing retinal damage & inflammation in a dose related response in both the M & C groups except for the 0.025 mg/0.1 ml concentration of M & the NS group which were within normal limits.

Conclusion: Our multitest regimen established that IV Micafungin at a dose of 0.025 mg/0.1 ml (8.3X minimum inhibitory concentrations (MIC) for Candida species in rabbit vitreous and 3.1X MIC for Candida species in human vitreous) is a non-toxic starting point for animal studies of antimicrobial efficacy and future use in humans for treatment of fungal endophthalmitis.

Keywords: endophthalmitis • fungal disease • drug toxicity/drug effects

© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH